A new depression scale designed to be sensitive to change
- PMID: 444788
- DOI: 10.1192/bjp.134.4.382
A new depression scale designed to be sensitive to change
Abstract
The construction of a depression rating scale designed to be particularly sensitive to treatment effects is described. Ratings of 54 English and 52 Swedish patients on a 65 item comprehensive psychopathology scale were used to identify the 17 most commonly occurring symptoms in primary depressive illness in the combined sample. Ratings on these 17 items for 64 patients participating in studies of four different antidepressant drugs were used to create a depression scale consisting of the 10 items which showed the largest changes with treatment and the highest correlation to overall change. The inner-rater reliability of the new depression scale was high. Scores on the scale correlated significantly with scores on a standard rating scale for depression, the Hamilton Rating Scale (HRS), indicating its validity as a general severity estimate. Its capacity to differentiate between responders and non-responders to antidepressant treatment was better than the HRS, indicating greater sensitivity to change. The practical and ethical implications in terms of smaller sample sizes in clinical trials are discussed.
Similar articles
-
Differential effects on suicidal ideation of mianserin, maprotiline and amitriptyline.Br J Clin Pharmacol. 1978;5 Suppl 1(Suppl 1):77S-80S. Br J Clin Pharmacol. 1978. PMID: 341948 Free PMC article. Clinical Trial.
-
Relative speed of onset of the antidepressant effect of maprotiline.Clin Ther. 1981;3(5):374-81. Clin Ther. 1981. PMID: 7471133
-
Comparison of the efficacy of sustained-release amitriptyline with maprotiline in the treatment of depressive illness.Curr Med Res Opin. 1980;6(8):534-9. doi: 10.1185/03007998009109483. Curr Med Res Opin. 1980. PMID: 7389384 Clinical Trial.
-
Maprotiline, nomifensine, mianserin, zimelidine: a review of antidepressant efficacy in in-patients.Neuropharmacology. 1980 Dec;19(12):1185-90. doi: 10.1016/0028-3908(80)90199-9. Neuropharmacology. 1980. PMID: 6449677 Review. No abstract available.
-
A risk-benefit assessment of mirtazapine in the treatment of depression.Drug Saf. 1997 Oct;17(4):251-64. doi: 10.2165/00002018-199717040-00005. Drug Saf. 1997. PMID: 9352961 Review.
Cited by
-
TRPC4/5 inhibitors: Phase I results and proof of concept studies.Eur Arch Psychiatry Clin Neurosci. 2024 Sep 29. doi: 10.1007/s00406-024-01890-0. Online ahead of print. Eur Arch Psychiatry Clin Neurosci. 2024. PMID: 39343822 Review.
-
Comprehensive MRI assessment reveals subtle brain findings in non-hospitalized post-COVID patients with cognitive impairment.Front Neurosci. 2024 Sep 10;18:1435218. doi: 10.3389/fnins.2024.1435218. eCollection 2024. Front Neurosci. 2024. PMID: 39319311 Free PMC article.
-
Genetic underpinnings of YMRS and MADRS scores variations in a bipolar sample.Eur Arch Psychiatry Clin Neurosci. 2024 Sep 23. doi: 10.1007/s00406-024-01878-w. Online ahead of print. Eur Arch Psychiatry Clin Neurosci. 2024. PMID: 39313733
-
Making the most out of timeseries symptom data: A machine learning study on symptom predictions of internet-based CBT.Internet Interv. 2024 Sep 12;38:100773. doi: 10.1016/j.invent.2024.100773. eCollection 2024 Dec. Internet Interv. 2024. PMID: 39310714 Free PMC article.
-
Older adults make sense of their suicidal behavior: a Swedish interview study.Front Psychiatry. 2024 Sep 3;15:1450683. doi: 10.3389/fpsyt.2024.1450683. eCollection 2024. Front Psychiatry. 2024. PMID: 39310661 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources